Search clinical trials for: Safety and Immunogenicity

Total 474886 results

Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
PharmaJet, Inc.
United States Department of Defense

Active, not recruiting

Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection

Vaccine Reaction

United States
Dynavax Technologies Corporation
United States Department of Defense

Completed

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

Vaccine-Preventable Diseases | Plague | Plague, Pneumonic

United States
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Pneumococcal Infections

United States
Vaxart

Completed

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines (VXA-NVV-105)

Norovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults

HIV Infections

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Malaria

Ghana, Kenya
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults

Schistosomiasis

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

Dengue Virus | Dengue Disease

United States, Australia, Canada, Finland, Germany, Israel, Taiwan
Hipra Scientific, S.L.U

Active, not recruiting

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

SARS-CoV2 Infection

Spain
Shanghai Henlius Biotech

Completed

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

Breast Cancer

China, Ukraine, Philippines
VBI Vaccines Inc.

Completed

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Covid19

Canada
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
University of Oxford
MRC/UVRI and LSHTM Uganda Research Unit

Active, not recruiting

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Malaria

Uganda
Seqirus
Biomedical Advanced Research and Development Authority

Active, not recruiting

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

Infections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection Viral

United States
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine (COVID-19)

COVID-19 | Influenza

Australia, New Zealand
National Institute of Allergy and Infectious Diseases...

Terminated

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

H3N2 Influenza

United States
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
AstraZeneca

Active, not recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
H. Lundbeck A/S

Active, not recruiting

A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults

Healthy Participants

China
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)

Pneumonia, Pneumococcal

United States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
IrsiCaixa
José Moltó Marhuenda, PhD, MD; Beatriz Mothe Pujadas PhD,MD; Susana Benet Garrabé... and other collaborators

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

HIV Infection

Spain
IrsiCaixa
Hospital Clinic of Barcelona; University of Oxford; Fundación FLS de Lucha Contra... and other collaborators

Completed

Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals

HIV

Spain
Butantan Institute
Valneva Austria GmbH

Completed

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Chikungunya

Brazil
International AIDS Vaccine Initiative
Emory University; Fred Hutchinson Cancer Center; George Washington University; ModernaTX... and other collaborators

Active, not recruiting

A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)

Hiv

United States
Altimmune, Inc.

Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Influenza

United States
Centre Hospitalier Universitaire de Saint Etienne

Active, not recruiting

Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen (CoviCompare_J)

Healthy Volunteers

France
mAbxience Research S.L.

Active, not recruiting

A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)

Postmenopausal Women With Osteoporosis

Poland, Serbia, Bulgaria, Georgia, Estonia, Hungary, Latvia, Mexico
National Institute of Allergy and Infectious Diseases...
Moderna TX, Inc

Active, not recruiting

Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults

Nipah Virus Infection

United States
Luye Pharma Group Ltd.

Active, not recruiting

Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal

Poland, United States, Czechia, Bulgaria, Japan
WestVac Biopharma Co., Ltd.
West China Hospital

Completed

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

China
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036) (PNEU-PED-KOR)

Pneumococcal Disease

Korea, Republic of
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Cytomegalovirus Infection

United States, Australia, Canada, France, Belgium, Germany, Israel, Italy, United Kingdom, Spain, Estonia, Finland, Japan
WestVac Biopharma Co., Ltd.

Completed

Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Philippines
Suzhou Abogen Biosciences Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine

COVID-19

Philippines, Pakistan, United Arab Emirates, Indonesia
Institut Pasteur
Wellcome Trust; Walter Reed Army Institute of Research (WRAIR); Parexel; Bill &... and other collaborators

Completed

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a (GlycoShig3)

Healthy

Kenya
WestVac Biopharma Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster

COVID-19 | SARS-CoV-2 Infection

Mexico
Biocon Biologics Inc.
MEDA Pharma GmbH & Co. KG; Mylan Inc.; IQVIA Pvt. Ltd

Completed

Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity

Moderate Chronic Plaque Psoriasis | Severe Chronic Plaque Psoriasis

Bulgaria, Czechia, Estonia, Poland
GlaxoSmithKline
CureVac

Completed

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

Influenza, Human

Belgium, Spain, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
University of Bergen
Norwegian University of Science and Technology; International Centre for Diarrhoeal...

Active, not recruiting

An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh (FluEffect)

Influenza Viral Infections

Bangladesh, Norway
GlaxoSmithKline

Completed

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

China
National Institute of Allergy and Infectious Diseases...

Completed

Anthrax AV7909 Liquid vs Lyophilized

Anthrax | Anthrax Immunisation

United States
Vaxcyte, Inc.

Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Pneumococcal Vaccines

United States

3

Subscribe